Trials / Completed
CompletedNCT01330966
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Emerald Clinical Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.
Detailed description
This research study is being conducted in adult subjects with a type of bone cancer called chondrosarcoma that has spread to other parts of the body and is not able to be removed with surgery. There is only one study drug that will be used in this study. It is a drug that interferes with cell communication and growth, taken orally. The study drug is called pazopanib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pazopanib | Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2018-02-01
- Completion
- 2018-02-01
- First posted
- 2011-04-07
- Last updated
- 2023-03-10
- Results posted
- 2020-02-12
Locations
7 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT01330966. Inclusion in this directory is not an endorsement.